LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced that the first participants have been vaccinated in a phase 1 ...

CARB-X awards LimmaTech US$6.5 million to advance clinical development of LBT-SA7 “We are grateful for the significant support from CARB-X, which is not only instrumental in accelerating the clinical ...

ZURICH, Switzerland I February 17, 2025 I LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first ...